<?xml version='1.0' encoding='utf-8'?>
<document id="17518513"><sentence text="Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction?" /><sentence text="Suppression of prostacyclin (PGI2) is implicated in the cardiovascular hazard from inhibitors of cyclooxygenase (COX)-2"><entity charOffset="15-27" id="DDI-PubMed.17518513.s2.e0" text="prostacyclin" /><entity charOffset="29-33" id="DDI-PubMed.17518513.s2.e1" text="PGI2" /><pair ddi="false" e1="DDI-PubMed.17518513.s2.e0" e2="DDI-PubMed.17518513.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17518513.s2.e0" e2="DDI-PubMed.17518513.s2.e1" /></sentence><sentence text=" Furthermore, estrogen confers atheroprotection via COX-2-dependent PGI2 in mice, raising the possibility that COX inhibitors may undermine the cardioprotection, suggested by observational studies, of endogenous or exogenous estrogens"><entity charOffset="14-22" id="DDI-PubMed.17518513.s3.e0" text="estrogen" /><entity charOffset="225-234" id="DDI-PubMed.17518513.s3.e1" text="estrogens" /><entity charOffset="68-76" id="DDI-PubMed.17518513.s3.e2" text="PGI2" /><pair ddi="false" e1="DDI-PubMed.17518513.s3.e0" e2="DDI-PubMed.17518513.s3.e0" /><pair ddi="false" e1="DDI-PubMed.17518513.s3.e0" e2="DDI-PubMed.17518513.s3.e2" /><pair ddi="false" e1="DDI-PubMed.17518513.s3.e0" e2="DDI-PubMed.17518513.s3.e1" /><pair ddi="false" e1="DDI-PubMed.17518513.s3.e2" e2="DDI-PubMed.17518513.s3.e2" /><pair ddi="false" e1="DDI-PubMed.17518513.s3.e2" e2="DDI-PubMed.17518513.s3.e1" /></sentence><sentence text="" /><sentence text="To identify an interaction between hormone therapy (HT) and COX inhibition, we measured a priori the association between concomitant nonsteroidal anti-inflammatory drugs (NSAIDs), excluding aspirin, in peri- and postmenopausal women on HT and the incidence of myocardial infarction (MI) in a population-based epidemiological study"><entity charOffset="190-197" id="DDI-PubMed.17518513.s5.e0" text="aspirin" /></sentence><sentence text=" The odds ratio (OR) of MI in 1,673 individuals and 7,005 controls was increased from 0" /><sentence text="66 (95% confidence interval [CI] 0" /><sentence text="50-0" /><sentence text="88) when taking HT in the absence of traditional (t)NSAIDs to 1" /><sentence text="50 (95% CI 0" /><sentence text="85-2" /><sentence text="64) when taking the combination of HT and tNSAIDs, resulting in a significant (p &lt; 0" /><sentence text="002) interaction" /><sentence text=" The OR when taking aspirin at doses of 150 mg/d or more was 1"><entity charOffset="20-27" id="DDI-PubMed.17518513.s14.e0" text="aspirin" /></sentence><sentence text="41 (95% CI 0" /><sentence text="47-4" /><sentence text="22)" /><sentence text=" However, a similar interaction was not observed with other commonly used drugs, including lower doses of aspirin, which target preferentially COX-1"><entity charOffset="106-113" id="DDI-PubMed.17518513.s18.e0" text="aspirin" /></sentence><sentence text="" /><sentence text="Whether estrogens confer cardioprotection remains controversial"><entity charOffset="8-17" id="DDI-PubMed.17518513.s20.e0" text="estrogens" /></sentence><sentence text=" Such a benefit was observed only in perimenopausal women in the only large randomized trial designed to address this issue" /><sentence text=" Should such a benefit exist, these results raise the possibility that COX inhibitors may undermine the cardioprotective effects of HT" /><sentence text="" /></document>